The widely promoted 150-minute-per-week physical activity guideline has long served as a public health benchmark, but a mounting body of evidence suggests it represents a floor, not a ceiling, for cardiovascular protection. This large-scale analysis clarifies precisely how much further beyond that threshold meaningful risk reduction actually lies — and the answer should reframe how clinicians and health-conscious individuals think about exercise volume targets.
Drawing on accelerometer data from 17,088 UK Biobank participants followed for a median of nearly eight years, the analysis deployed Cox generalised additive models to map the joint relationship between moderate-to-vigorous physical activity (MVPA) and cardiorespiratory fitness — estimated as VO₂max — against incident cardiovascular disease, including atrial fibrillation, myocardial infarction, heart failure, and stroke. The key finding: while meeting the standard 150 minutes per week guideline was associated with only a modest 8–9% cardiovascular risk reduction regardless of fitness level, achieving a greater than 30% risk reduction required three to four times that volume, approximately 560–610 minutes per week. A significant non-linear interaction between MVPA and cardiorespiratory fitness was confirmed statistically, and Mendelian randomisation analyses using genome-wide association study summary statistics provided complementary causal evidence supporting these associations.
This work is notable for several reasons beyond its scale. The use of device-measured activity — rather than self-reported data, which is notoriously unreliable — substantially strengthens observational validity. The Mendelian randomisation component, while not replacing a randomised trial, helps disentangle confounding that plagues traditional cohort approaches, lending a degree of causal credibility rare in exercise epidemiology. The fitness-stratified matrix is a particularly practical innovation, enabling risk-stratified activity targets based on individual VO₂max estimates. Key limitations include the UK Biobank's well-documented healthy volunteer bias, a predominantly middle-aged White European cohort, and the use of estimated rather than directly measured VO₂max. Nonetheless, this is a methodologically sophisticated, confirmatory-yet-escalating finding — one that should prompt serious reconsideration of whether current guidelines adequately reflect the dose needed for substantial cardiovascular benefit.
